[go: up one dir, main page]

DK4161935T3 - Brm-målrettende forbindelser og tilhørende anvendelsesmetoder - Google Patents

Brm-målrettende forbindelser og tilhørende anvendelsesmetoder

Info

Publication number
DK4161935T3
DK4161935T3 DK21736890.1T DK21736890T DK4161935T3 DK 4161935 T3 DK4161935 T3 DK 4161935T3 DK 21736890 T DK21736890 T DK 21736890T DK 4161935 T3 DK4161935 T3 DK 4161935T3
Authority
DK
Denmark
Prior art keywords
brm
related application
application methods
targeting compounds
targeting
Prior art date
Application number
DK21736890.1T
Other languages
English (en)
Inventor
Andrew Paul Combs
Hong Lin
Philip Pitis
Liang Lu
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Application granted granted Critical
Publication of DK4161935T3 publication Critical patent/DK4161935T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
DK21736890.1T 2020-06-09 2021-06-09 Brm-målrettende forbindelser og tilhørende anvendelsesmetoder DK4161935T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063036811P 2020-06-09 2020-06-09
PCT/US2021/036664 WO2021252666A1 (en) 2020-06-09 2021-06-09 Brm targeting compounds and associated methods of use

Publications (1)

Publication Number Publication Date
DK4161935T3 true DK4161935T3 (da) 2025-08-18

Family

ID=76731093

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21736890.1T DK4161935T3 (da) 2020-06-09 2021-06-09 Brm-målrettende forbindelser og tilhørende anvendelsesmetoder

Country Status (16)

Country Link
US (2) US11702423B2 (da)
EP (2) EP4161935B1 (da)
JP (1) JP2023529908A (da)
KR (1) KR20230037549A (da)
CN (1) CN115867554B (da)
AU (1) AU2021289730A1 (da)
BR (1) BR112022025061A2 (da)
CA (1) CA3185888A1 (da)
DK (1) DK4161935T3 (da)
ES (1) ES3034380T3 (da)
FI (1) FI4161935T3 (da)
IL (1) IL298933A (da)
MX (1) MX2022015732A (da)
PL (1) PL4161935T3 (da)
PT (1) PT4161935T (da)
WO (1) WO2021252666A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
CA3162502A1 (en) 2019-12-23 2021-07-01 Yi Zhang Smarca degraders and uses thereof
CA3200685A1 (en) * 2020-11-06 2022-05-12 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
EP4363425A4 (en) * 2021-06-28 2025-05-14 Kymera Therapeutics, Inc. SMARCA DEGRADERS AND USES THEREOF
US11993599B2 (en) * 2021-08-09 2024-05-28 Genentech, Inc. Therapeutic compounds
CN120035593A (zh) * 2022-05-10 2025-05-23 福宏治疗公司 吡嗪衍生物及其用途
IL316891A (en) * 2022-05-10 2025-01-01 Prelude Therapeutics Inc BRM-targeted compounds and related methods of use
WO2024064328A1 (en) * 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 degraders and uses thereof
WO2024064316A1 (en) * 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 inhibitors and uses thereof
CN120152970A (zh) * 2022-10-03 2025-06-13 普莱鲁德疗法有限公司 使用smarca2降解剂和kras靶向疗法的组合实现的癌症治疗
EP4695250A1 (en) 2023-04-12 2026-02-18 Aurigene Oncology Limited Tetracyclic compounds as smarca2 and/or smarca4 degraders
WO2025076357A1 (en) 2023-10-04 2025-04-10 Prelude Therapeutics Incorporated Combination treatment regimens - smarca2 degrader with taxane anticancer agent
US20250114353A1 (en) 2023-10-04 2025-04-10 Prelude Therapeutics Incorporated Combination Treatment Regimens - SMARCA2 Degrader With Gemcitabine
US20250114354A1 (en) 2023-10-04 2025-04-10 Prelude Therapeutics Incorporated Combination treatment regimens - smarca2 degrader with pd-1 inhibitors
WO2025106482A1 (en) * 2023-11-13 2025-05-22 Oncopia Therapeutics, Inc. D/B/A Sk Life Science Labs Compounds and compositions as smarca2/4 degraders and uses thereof
WO2025193454A1 (en) 2024-03-01 2025-09-18 Prelude Therapeutics Incorporated Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
CN119638700B (zh) * 2024-11-01 2025-11-14 中科中山药物创新研究院 一种nsd2降解剂及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
MA41598A (fr) * 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
GB2554071A (en) 2016-09-14 2018-03-28 Univ Dundee Small molecules
US10723717B2 (en) 2016-12-23 2020-07-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
CA3049912A1 (en) 2017-01-26 2018-08-02 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
EP3700901A1 (en) 2017-10-24 2020-09-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
EP3774789B1 (en) 2018-04-01 2025-03-05 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
US12539292B2 (en) 2018-04-01 2026-02-03 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2020251974A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
US20230087825A1 (en) 2019-06-10 2023-03-23 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2020251971A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
CA3162502A1 (en) * 2019-12-23 2021-07-01 Yi Zhang Smarca degraders and uses thereof
CA3200685A1 (en) * 2020-11-06 2022-05-12 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use

Also Published As

Publication number Publication date
US20240018158A1 (en) 2024-01-18
CA3185888A1 (en) 2021-12-16
IL298933A (en) 2023-02-01
MX2022015732A (es) 2023-02-13
EP4161935A1 (en) 2023-04-12
US20220033409A1 (en) 2022-02-03
FI4161935T3 (fi) 2025-08-19
PL4161935T3 (pl) 2025-09-08
PT4161935T (pt) 2025-08-14
CN115867554B (zh) 2025-09-02
EP4570319A2 (en) 2025-06-18
EP4570319A3 (en) 2025-08-20
CN115867554A (zh) 2023-03-28
JP2023529908A (ja) 2023-07-12
EP4161935B1 (en) 2025-05-21
AU2021289730A1 (en) 2023-01-19
ES3034380T3 (en) 2025-08-18
US11702423B2 (en) 2023-07-18
BR112022025061A2 (pt) 2023-01-31
KR20230037549A (ko) 2023-03-16
AU2021289730A8 (en) 2023-02-02
WO2021252666A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
DK4161935T3 (da) Brm-målrettende forbindelser og tilhørende anvendelsesmetoder
DK3917616T3 (da) Heterocykliske forbindelser og anvendelse deraf
DK3946464T3 (da) Forbindelser og konjugater deraf
DK4196479T3 (da) Substituerede pyridotriazinforbindelser og anvendelser deraf
DK3774789T3 (da) BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
EP4216951A4 (en) KRAS G12D INHIBITORS
DK3870579T3 (da) Tyk2-inhibitorer og anvendelser deraf
DK3932919T3 (da) Jak-inhibitorforbindelse og anvendelse deraf
DK3788044T3 (da) RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf
DK3947375T3 (da) Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf
DK3704227T3 (da) Sammensætning og fremgangsmåde
EP4281085A4 (en) MODIFIED DOUBLE-STRANDED OLIGONUCLEOTIDES
DK3892621T3 (da) Haloallylaminforbindelser og anvendelse deraf
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3710485T3 (da) Anti-sez6-antistof-lægemiddelkonjugater og anvendelsesfremgangsmåder
DK3960260T3 (da) Kropsbåren enhed og metode deraf
DK4028631T3 (da) Borehulsfremgangsmåde og tilhørendde anordning
DK3919498T6 (da) Pyrrolopyrimidinderivat og anvendelse deraf
DK3615502T3 (da) Terapeutiske forbindelser og fremgangsmåder
DK4153496T3 (da) Emne og kasse opnåelig derfra
EP4247372A4 (en) PLASMA KALLICREIN INHIBITORS
DK4073346T3 (da) Borehulsværktøj og fremgangsmåder
DK3932909T3 (da) Benzoindazolonforbindelse og mellemprodukt heraf
IL309079A (en) Methods and compositions
EP4226919A4 (en) FERROPTOSIS INHIBITOR